WeVote
Log In

Bill

Bill

LC 3969

Study psilocybin for medical uses

2025 Regular Session

Montana's proposed psilocybin medical research study bill died in drafting without advancing to formal legislative consideration.

(LC) Draft Died in Process
#legislature #health #interimstudyresolutions #safety
0
WeVote Research Nonpartisan
Bill Summary · LC 3969

Legislative bill overview

LC 3969 is a Montana legislative concept bill that would have authorized a study on psilocybin's potential medical applications. The bill died in the drafting process in May 2025 before advancing to formal introduction, meaning it never became an actual legislative proposal for committee review or floor debate.

Why this is important

Psilocybin research has gained scientific momentum nationally, with FDA designation of psilocybin-assisted therapy as a "breakthrough therapy" for treatment-resistant depression. A state-level study could have positioned Montana to evaluate clinical applications, inform future policy decisions, and potentially unlock therapeutic options for patients with limited treatment alternatives. The bill's failure means Montana won't currently pursue this research pathway.

Potential points of contention

  • Federal-state legal conflict: Psilocybin remains a Schedule I controlled substance federally, creating tension between state research authorization and federal law enforcement
  • Regulatory uncertainty: Unclear who would conduct the study, what oversight mechanisms would apply, and whether federal approval would be required
  • Resource allocation: Questions about whether state funding for psilocybin research represents appropriate use of limited medical research budgets versus other health priorities

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.